Belite Bio (BLTE) Operating Expenses (2022 - 2026)

Belite Bio (BLTE) has reported Operating Expenses for 5 consecutive years, with $32.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 110.63% year-over-year to $32.7 million; the TTM figure through Mar 2026 stood at $68.7 billion (up 116.91% YoY), while the FY2025 annual figure was $84.2 million, up 110.54% from the prior year.
• Operating Expenses came in at $32.7 million for Q1 2026 at Belite Bio, down from $28.1 billion in the prior quarter.
• The five-year high for Operating Expenses was $28.1 billion in Q4 2025, with the low at $6.7 million in Q4 2022.
• Average Operating Expenses over 5 years is $8.0 billion, with a median of $6.9 billion recorded in 2023.
• Across the five-year window, Operating Expenses soared 164630.41% in 2024 and slumped 99.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $6.7 million in 2022, then advanced by 3.48% to $7.0 million in 2023, then jumped by 164630.41% to $11.5 billion in 2024, then jumped by 145.06% to $28.1 billion in 2025, then slumped by 99.88% to $32.7 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $32.7 million, $28.1 billion, and $23.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.